US 12,093,681 B2
Ambulatory medicament device with security override passcode
Michael J. Rosinko, Las Vegas, NV (US); Himanshu Patel, Rancho Santa Margarita, CA (US); Edward R. Damiano, Acton, MA (US); and Firas H. El-Khatib, Allston, MA (US)
Assigned to Beta Bionics, Inc., Concord, MA (US)
Filed by Beta Bionics, Inc., Irvine, CA (US)
Filed on Sep. 27, 2021, as Appl. No. 17/486,784.
Application 17/486,784 is a continuation of application No. 17/062,399, filed on Oct. 2, 2020, granted, now 11,135,365.
Application 17/062,399 is a continuation in part of application No. PCT/US2020/042195, filed on Jul. 15, 2020.
Claims priority of provisional application 63/037,472, filed on Jun. 10, 2020.
Claims priority of provisional application 62/987,842, filed on Mar. 10, 2020.
Claims priority of provisional application 62/910,970, filed on Oct. 4, 2019.
Claims priority of provisional application 62/911,017, filed on Oct. 4, 2019.
Claims priority of provisional application 62/911,143, filed on Oct. 4, 2019.
Claims priority of provisional application 62/874,950, filed on Jul. 16, 2019.
Claims priority of provisional application 62/874,968, filed on Jul. 16, 2019.
Claims priority of provisional application 62/874,934, filed on Jul. 16, 2019.
Prior Publication US 2022/0080121 A1, Mar. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61M 5/172 (2006.01); A61M 5/142 (2006.01); A61M 5/168 (2006.01); G06F 3/04847 (2022.01); G06F 3/04883 (2022.01); G06F 8/61 (2018.01); G06F 8/65 (2018.01); G06F 8/656 (2018.01); G06F 21/30 (2013.01); G06F 21/31 (2013.01); G06F 21/62 (2013.01); G06F 21/84 (2013.01); G08B 21/04 (2006.01); G08B 21/18 (2006.01); G16H 10/60 (2018.01); G16H 20/17 (2018.01); G16H 40/40 (2018.01); G16H 40/60 (2018.01); G16H 40/67 (2018.01); G16H 50/30 (2018.01); G16H 80/00 (2018.01); H04L 9/08 (2006.01); H04L 9/30 (2006.01); H04L 9/40 (2022.01); H04L 67/00 (2022.01); H04W 76/10 (2018.01); H04W 76/14 (2018.01); A61B 5/145 (2006.01); G08B 25/00 (2006.01); G16H 40/00 (2018.01)
CPC G06F 8/656 (2018.02) [A61M 5/142 (2013.01); A61M 5/14244 (2013.01); A61M 5/14248 (2013.01); A61M 5/16831 (2013.01); A61M 5/172 (2013.01); G06F 3/04847 (2013.01); G06F 3/04883 (2013.01); G06F 8/61 (2013.01); G06F 8/65 (2013.01); G06F 21/305 (2013.01); G06F 21/31 (2013.01); G06F 21/6245 (2013.01); G06F 21/84 (2013.01); G08B 21/0453 (2013.01); G08B 21/18 (2013.01); G16H 10/60 (2018.01); G16H 20/17 (2018.01); G16H 40/40 (2018.01); G16H 40/60 (2018.01); G16H 40/67 (2018.01); G16H 50/30 (2018.01); G16H 80/00 (2018.01); H04L 9/088 (2013.01); H04L 9/30 (2013.01); H04L 63/101 (2013.01); H04L 67/34 (2013.01); H04W 76/10 (2018.02); H04W 76/14 (2018.02); A61B 5/14532 (2013.01); A61M 2005/14208 (2013.01); A61M 5/1723 (2013.01); A61M 2005/1726 (2013.01); A61M 2205/18 (2013.01); A61M 2205/3327 (2013.01); A61M 2205/3546 (2013.01); A61M 2205/3553 (2013.01); A61M 2205/3584 (2013.01); A61M 2205/3592 (2013.01); A61M 2205/50 (2013.01); A61M 2205/502 (2013.01); A61M 2205/505 (2013.01); A61M 2205/52 (2013.01); A61M 2205/581 (2013.01); A61M 2205/582 (2013.01); A61M 2205/583 (2013.01); A61M 2205/609 (2013.01); A61M 2230/201 (2013.01); G08B 25/00 (2013.01); G16H 40/00 (2018.01)] 31 Claims
OG exemplary drawing
 
1. A glucose level control system configured to generate a dose output for administration of medicament to a subject and configured to secure at least some functionality of a user interface of the glucose level control system, the glucose level control system comprising:
a display interface configured to output display signals configured to generate user interface screens;
a memory configured to store specific computer-executable instructions, a user-generated passcode that is selected by a user during a passcode-setting process, and an override passcode that is not selected by the user; and
a hardware processor in communication with the memory and configured to execute the specific computer-executable instructions to at least:
generate a dose output using a control algorithm employing control parameters, wherein at least one control parameter of the control parameters can be modified by a user interaction with a parameter control element;
determine that the parameter control element is protected by a security process;
in response to the user interaction with a user input element associated with the parameter control element protected by the security process, generate a passcode display of a keypad comprising user-selectable letters, numbers, symbols, or a combination thereof, wherein the keypad is configured to accept user input of a security code;
validate the security code to confirm that the user is authorized to modify the at least one control parameter via the parameter control element protected by the security process by confirming that the security code matches the user-generated passcode or the override passcode; and
in response to validating the security code, permit modification of the at least one control parameter via the parameter control element.